Meet Ms Janine Rolfe, Cynata’s (ASX:CYP) new Non-Executive Director - Kalkine Media

Highlights

• Ms Janine Rolfe has joined Cynata as an independent Non-Executive Director
• Ms Rolfe has more than 20 years of expertise in executive roles within different industry sectors, and she has worked both in-house and in private legal practice

Cynata Therapeutics Limited (ASX:CYP), a cell therapeutics company, onboards Ms Janine Rolfe as a new independent Non-Executive Director. The new appointment will be effective from 1 September 2022.

Ms Rolfe has over 20 years of experience in different industry sectors, where her various roles have included management, legal and governance. She has worked with complex global businesses and highly regulated industries. Before joining Cynata, Ms Rolfe worked with Link Administration Holdings Limited (Link Group), as General Counsel & Company Secretary. Prior to that position, she established Company Matters Pty Limited. She has worked both in-house (Qantas Airways Limited) and in private practice (Mallesons Stephen Jaques, now King & Wood Mallesons). Ms Rolfe is a member of the Australian Institute of Company Directors (AICD) and received a Bachelor of Economics and Bachelor of Laws (Honours) from the University of Sydney.

Image: © 2022 Kalkine Media®

Embed video

Cynata Therapeutics elaborates on its strong pipeline of clinical opportunities

About Cynata

Cynata specialises in stem cell and regenerative medicine, developing therapies based on its proprietary platform technology, Cymerus™.

Image: © 2022 Kalkine Media®

CYP-001 is the company’s lead product. It has proven positive safety and efficacy data for treating steroid-resistant acute graft-versus-host disease (aGvHD) in a Phase 1 trial. Presently, the company is planning a Phase 2 clinical trial in GvHD under a cleared IND from the US FDA.

Words from the new member

Image: © 2022 Kalkine Media®

Publication in a reputed journal

In a recent announcement, Cynata mentioned that the results of its research work describing the optimisation of Cymerus™ mesenchymal stem cells (MSCs) for the treatment of coronary artery disease (CAD) had been published in the Journal of Tissue Engineering and Regenerative Medicine. It is a highly reputed peer-reviewed journal, and Cynata undertook the study in collaboration with UNSW Sydney (the University of New South Wales). These exciting results suggest that Cymerus MSCs could play an important part in the management of CAD.